Background

Septa Therapeutics' technology is designed to block the inflammation characteristic of Alzheimer's Disease (AD). Our approach is entirely new. However, it is based on 20 years of academic research in chronic infrection in the Central Nervous System (CNS) and 5 years of meningitis-related research.

The early research has been completed and is summarized in three issued patents (see Technology).

We are currently in the enviable position to quickly capitalize on this early work to develop a new drug candidate for the treatment of AD.

Pre-clinical trials

Septa Therapeutics has devoted the entire year of 2024 to the development of a series of inflammation blockers. We have employed Cellulose-bound Peptide Arrays to construct blockers which will pass through nasal membranes, bind to Amyloid-beta in the brain and which meet all new US patent office requirements for patentability. These latter requirements have been connected to recent political changes occurring since our earlier filing in 2018.

Pre-clinical trials have been initiated with Charles River Discovery Research Services Finland, Ltd. We are now preparing to initiate Phase 1 trials using Tg2576 mice. These studies are designed to show that early administration of our new drug candidate will prevent, or greatly delay the onset of AD.